Interested in learning more about our screening programs or partnerships?
Please contact us at email@example.com
Breast cancer is the most lethal cancer in women across the world. In Europe, 1 out of 8 women will develop breast cancer before the age of 85 and 20% of cases occur in women younger than 50. Current breast cancer screening guidelines are primarily based on age and do not support regular screening of women below the age of 50. This largely excludes young women with high a genetic risk of developing breast cancer. It is no longer appropriate to apply identical recommendations to all women across all age groups and risk profiles. A more precise and personalized risk stratification approach is needed.
The use of genetic information allows better stratification of women at a higher risk of developing breast cancer. The genetic risks in breast cancer have been estimated to contribute around 31% of the total risk whereas environmental factors add an additional 16%. Screening programs should use this information to individualize attendance recommendations.
Antegenes has developed a polygenic risk score test for breast cancer – AnteBC, which can differentiate polygenic predisposition to breast cancer. AnteBC is an important component of a comprehensive precision prevention program for breast cancer. The program relies on both the polygenic risk scores approach to create adjusted screening designs for individual women and, if appropriate, supports testing for rare high-risk monogenic mutations.
The program includes the use of the AnteBC test and is suitable for women aged 30 – 75.